SalaryGuide
AboutPricingFor Employers

Marketing jobs

7 marketing jobs

Biogen logo
2 days ago

Associate Director, Neuropsychiatry - HCP Marketing

Biogen

Cambridge, MA (Hybrid)Full time$164K/yr – $226K/yr
Biogen logo
5 days ago

Director, HCP Marketing Alzheimer's

Biogen

Cambridge, MA (Hybrid)Full time$195K/yr – $269K/yr
Biogen logo
10 days ago

Head of Commercial CRM & Customer Engagement Excellence (Director)

Biogen

Cambridge, MA (Hybrid)Full time$196K/yr – $270K/yr
Biogen logo
10 days ago

Senior Director, Marketing, Rare Disease - Friedreich Ataxia (FA)

Biogen

Cambridge, MA (Hybrid)Full time$234K/yr – $322K/yr
Biogen logo
11 days ago

Associate Director, US Omnichannel/Digital Engagement

Biogen

Cambridge, MA (Hybrid)Full time$164K/yr – $226K/yr
Biogen logo
4 months ago

Director, Product Communications, Rare Disease

Biogen

Cambridge, MA (On-site)Full time$192K/yr – $264K/yr
Biogen logo
5 months ago

Director, Marketing Operations - PRC/MLR

Biogen

Cambridge, MA (On-site)Full time$190K/yr – $261K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

7 jobs
Biogen logo

Associate Director, Neuropsychiatry - HCP Marketing

Biogen

Cambridge, MA (Hybrid)

$164K/yr - $226K/yrIn-houseFull-timeManager5+ years exp.
2 days ago
Biogen logo

Director, HCP Marketing Alzheimer's

Biogen

Cambridge, MA (Hybrid)

$195K/yr - $269K/yrIn-houseFull-timeDirector/executive
5 days ago
Biogen logo

Head of Commercial CRM & Customer Engagement Excellence (Director)

Biogen

Cambridge, MA (Hybrid)

$196K/yr - $270K/yrIn-houseFull-timeDirector/executive7+ years exp.
10 days ago
Biogen logo

Senior Director, Marketing, Rare Disease - Friedreich Ataxia (FA)

Biogen

Cambridge, MA (Hybrid)

$234K/yr - $322K/yrIn-houseFull-timeSenior level12+ years exp.
10 days ago
Biogen logo

Associate Director, US Omnichannel/Digital Engagement

Biogen

Cambridge, MA (Hybrid)

$164K/yr - $226K/yrIn-houseFull-timeSenior level7+ years exp.
11 days ago
Biogen logo

Director, Product Communications, Rare Disease

Biogen

Cambridge, MA (On-site)

$192K/yr - $264K/yrIn-houseFull-timeDirector/executive10+ years exp.
4 months ago
Biogen logo

Director, Marketing Operations - PRC/MLR

Biogen

Cambridge, MA (On-site)

$190K/yr - $261K/yrIn-houseFull-timeDirector/executive
5 months ago
Biogen logo
Biogen

Associate Director, Neuropsychiatry - HCP Marketing

Cambridge, MA (Hybrid)

$164K/yr – $226K/yrManager5+ years expFull time

Posted 2 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own and optimize HCP marketing initiatives across OB/Gyn, Psychiatry, and Advanced Practitioner segments, guiding strategy, executions, and cross‑functional collaborations to drive measured impact.

  • Define targeting and go-to-market for key audiences
  • Lead content across omnichannel environments for HCPs
  • Measure program performance and refine tactics

Job Description

Responsibilities

  • Ensure specific HCP promotional initiatives, including marketing programs and campaigns, are executed effectively, efficiently, within budget and in accordance with all regulatory/legal requirements.
  • Cultivate strong relationships with alliance partner, cross-functional partners, and all agencies. Manage relationship with agency to ensure expected deliverables are met.
  • Lead OB/Gyn, Psychiatry and Advanced Practitioner marketing initiatives in close collaboration with our collaboration partner and other key functional partners.
  • Lead key components of HCP strategy, including targeting, segmentation and go to market evolution for OB/Gyn, Psychiatry and Advanced Practitioner audiences
  • Lead communications plan for key HCP audiences
  • Plan and execute all engaging content across personal and key omnichannel environments for HCP audiences
  • Define strategy and tactical plan for supporting integrated systems to improve education and support for maternal mental health
  • Drive insight driven evolution of communications and tactics by analyzing/measuring program performance and leading customer-centric refinements

Requirements

  • Bachelor’s degree required; MBA preferred
  • Minimum of 5 years of pharmaceutical or biotech product marketing/commercial experience. Proven track record of success.

Preferred

  • Experience within Neuro-Psych, Women’s Health, PCP and/or specialty markets that cross-cut specialized and primary care audiences
  • Customer-facing experience
  • Experience working with an alliance partner
  • Prior product launch experience or working in underdeveloped marketplaces
  • Ability to deliver results in a fast-paced environment and “roll-up your sleeves” culture. A self-starter who functions well both independently and within a team.
  • Proven ability to manage multiple projects and priorities to meet deadlines.
  • Ability to think innovatively in terms of engaging with customers and meeting their needs.

Benefits

  • Medical, Dental, Vision, & Life insurances
  • Fitness & Wellness programs including a fitness reimbursement
  • Short- and Long-Term Disability insurance
  • A minimum of 15 days of paid vacation and an additional end-of-year shutdown time off (Dec 26-Dec 31)
  • Up to 12 company paid holidays + 3 paid days off for Personal Significance
  • 80 hours of sick time per calendar year
  • Paid Maternity and Parental Leave benefit
  • 401(k) program participation with company matched contributions
  • Employee stock purchase plan
  • Tuition reimbursement of up to $10,000 per calendar year
Biogen logo

Biogen

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities, to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.With approximately 7,000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Baar, Switzerland and we have world-class manufacturing facilities in North Carolina and Solothurn, Switzerland. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.For more information, please visit www.biogen.com. Community Guidelines: https://www.biogen.com/community-guidelines.htmlFollow us on social media – LinkedIn, Facebook, X, and YouTube.

Founded in 1978
Cambridge, Massachusetts, USA
7.5K employees (345 in marketing)
www.biogen.com

Traffic Signals

Monthly Visitors
173.7K
Traffic Source Mix
Search
55.8%
Direct
35.4%
Referral
6.7%
Social
1.2%
Paid
0.8%

Headcount Trend

Current headcount: ~7.5K

Marketing Team

Marketing Team Size
323 (4% of company)
Median Career Experience
18 years
Median Tenure
5.8 years
Marketing Roles Posted (Last 30 Days)
6

People

HR / Recruitment

Eileen Rivera
Eileen Rivera
Global Head, Total Rewards and Talent Acquisition
At the company for 15 years
Jordan R. Tieche
Jordan R. Tieche
Associate Director, TA | Talent Acquisition Site Lead - PO&T
At the company for 10 months

Marketing Leadership

Sundip Raval
Sundip Raval
Vice President, Head of Marketing, Rare Disease
At the company for 6 years 7 months
Odette Schweitzer
VP, Head of US Specialty Marketing
At the company for 6 years 11 months
Keri Shugrue, MBA
Keri Shugrue, MBA
Head of Marketing Operations
At the company for 4 years 1 month
Khurrum Ahmad
Khurrum Ahmad
Head of US Marketing, Alzheimer’s Franchise
At the company for 1 year 3 months

Funding

Total Funding
$1.5B
Last Raise
$1.5B
Post IPO Debt, 3 years ago

Funding History

  • Aug 2023
    Post IPO Debt • $1.5B

Recent News

Governor Stein Celebrates North Carolina’s Biotech Leadership As Biogen Highlights Recent $2 Billion Investment
Oct 9, 2025 • NC Governor (.gov)
Biogen Pledges $250,000 Donation to Durham Technical Community College to Mark 30th Year Anniversary in Research Triangle Park
Oct 9, 2025 • Biogen
Biogen told to pay $124M in patent dispute with Genentech
Oct 6, 2025 • Fierce Pharma
Biogen owes Genentech $88 million in MS drug dispute, US judge says
Oct 1, 2025 • Reuters
European court cancels Biogen’s extended market exclusivity for Tecfidera
Sep 30, 2025 • JUVE Patent
Biogen Shuffles 20 Staff After Ending AAV Work
Sep 29, 2025 • BioSpace
Bioarctic's Drug Leqembi Approved for Maintenance Dosing in China
Sep 29, 2025 • MarketScreener
Biogen, Eisai Say China Approves Maintenance Dosing Regimen for Alzheimer's Drug
Sep 29, 2025 • MarketScreener
Leqembi® approved for IV maintenance treatment in China
Sep 29, 2025 • Morningstar.com
Leqembi® approved for IV maintenance treatment in China
Sep 29, 2025 • News Powered by Cision
Leqembi® approved for IV maintenance treatment in China
Sep 29, 2025 • PR Newswire
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
Sep 28, 2025 • MarketScreener
San Francisco VA offers new therapies for early-stage Alzheimer’s
Sep 28, 2025 • Alaska VA Healthcare System
Biogen Inc. (BIIB): A Bull Case Theory
Sep 28, 2025 • Yahoo Finance
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
Sep 28, 2025 • BioSpace
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
Sep 28, 2025 • Biogen Inc.
Biogen officially ends all AAV gene therapy work, prompting team restructure
Sep 26, 2025 • Fierce Biotech
Lilly brings second oral SERD to market for breast cancer
Sep 26, 2025 • pharmaphorum
Lilly's Alzheimer’s drug Kisunla wins EC nod
Sep 26, 2025 • Pharma Letter
Trump’s drug tariffs are days away. Massachusetts’ pharma companies aren’t worried.
Sep 26, 2025 • Boston Globe
How a summer program shaped Eleanor Nkera's scientific journey
Sep 26, 2025 • Seattle TechFlash
Ophthalmology Drugs Market 2025: Trends, Growth, & Key Players Driving Global Eye Care Industry
Sep 26, 2025 • EIN Presswire
Drugs Market Size to Skyrocket USD 2895.42 Billion by 2034, reports Healthcare Specialists
Sep 26, 2025 • Precedence Research
Exclusive: Biogen calls it quits on AAV gene therapy, again
Sep 25, 2025 • Endpoints News
Biogen to Report Third Quarter 2025 Financial Results October 30, 2025
Sep 25, 2025 • Biogen
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
Sep 25, 2025 • BioSpace
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
Sep 24, 2025 • Biogen
Biogen plots resubmission after FDA turns down high-dose Spinraza in SMA, requests more production info
Sep 24, 2025 • Fierce Pharma
Biogen’s high-dose Spinraza turned down by FDA due to CMC troubles
Sep 24, 2025 • Pharmaceutical Technology
Leqembi® approved for the treatment of early Alzheimer's disease in Australia
Sep 24, 2025 • PR Newswire UK
US FDA declines to approve higher dose of Biogen's genetic disorder drug
Sep 23, 2025 • Reuters
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
Sep 23, 2025 • Biogen
Rtw biotech announces Biogen to acquire Alcyone Therapeutics
Sep 23, 2025 • MarketScreener
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
Sep 23, 2025 • Biogen Inc.
Biogen Provides Regulatory Update On High Dose Regimen Of Nusinersen
Sep 23, 2025 • Reuters
Biogen Says US FDA Delays Approval of Spinal Muscular Atrophy Treatment
Sep 23, 2025 • MarketScreener
RTW Biotech lifts NAV on Biogen's USD85 million Alcyone deal
Sep 23, 2025 • MarketScreener
FDA requests update to technical information of Biogen nusinersen sNDA
Sep 23, 2025 • thefly.com
BioPharma Credit buys back $50 mln shares, reports $72.8 mln profit in first half
Sep 22, 2025 • Investing.com
RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence
Sep 22, 2025 • PR Newswire UK
RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence
Sep 22, 2025 • PR Newswire
Biogen groundbreaking stirs optimism in Kendall Square
Sep 19, 2025 • WebWire
Biogen buys CNS delivery specialist Alcyone Therapeutics
Sep 19, 2025 • pharmaphorum
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
Sep 18, 2025 • Biogen
Biogen breaks ground on new Kendall Square headquarters
Sep 18, 2025 • statnews.com
Biogen strikes $85M Alcyone buyout, securing tech for spinal drug delivery
Sep 18, 2025 • Fierce Biotech
Biogen groundbreaking stirs optimism in Kendall Square
Sep 18, 2025 • MIT News
STAT+: Biogen breaks ground on new Kendall Square headquarters
Sep 18, 2025 • STAT
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
Sep 18, 2025 • Biogen Inc.
Jerome, you're in for a rough ride!
Sep 18, 2025 • MarketScreener
EC nod for Biogen’s PPD drug Zurzuvae
Sep 18, 2025 • Pharma Letter
Biogen to acquire Alcyone Therapeutics for $85M upfront cash payment
Sep 18, 2025 • thefly.com
T.Rx Capital Launches $77.5M Fund I to Invest in Bold Sta...
Sep 18, 2025 • PharmiWeb
Biogen acquires Lowell firm developing device meant replace the spinal tap
Sep 18, 2025 • Seattle TechFlash
Biogen's $85 Million Deal Could Change How Patients Get Spinraza Treatment
Sep 18, 2025 • Benzinga.com
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
Sep 18, 2025 • BioSpace
Biogen To Acquire Alcyone Therapeutics
Sep 18, 2025 • citybiz
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Sep 17, 2025 • Biogen
Biogen Gets EU Approval for Postpartum Depression Treatment
Sep 17, 2025 • MarketScreener
U.S. Biotechnology Market to Soar from USD 621.8 Billion in 2024 to USD 2004.86 Billion by 2034, Reports Towards Healthcare
Sep 17, 2025 • Precedence Research
Biogen receives European Commission approval for Zurzuvae
Sep 17, 2025 • MarketScreener
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Sep 17, 2025 • Biogen Inc.
Amid industry headwinds, Biogen breaks ground on new headquarters
Sep 16, 2025 • Boston Globe
C4 Therapeutics stock surges after Stephens upgrade signals upside
Sep 15, 2025 • Investing.com
Why C4 Therapeutics Stock Crushed the Market on Monday
Sep 15, 2025 • The Motley Fool
FDA Action Alert: Merck, Sanofi, Biogen and More
Sep 15, 2025 • BioSpace
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Sep 10, 2025 • Jeito Capital
Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated’ Pipeline
Sep 9, 2025 • BioSpace
Metaphore Biotechnologies Appoints Anabella Villalobos as Chief Scientific Officer
Sep 9, 2025 • citybiz
Lilly lines up Julianne Moore to front brain health campaign
Sep 9, 2025 • pharmaphorum
Metaphore Biotechnologies Expands Executive Leadership Team with Appointment of Anabella Villalobos as Chief Scientific Officer
Sep 9, 2025 • PR Newswire
Biogen Participating in the Morgan Stanley 23rd Annual Global Healthcare Conference
Sep 8, 2025 • Biogen
Why Biogen (BIIB) Is Up 6.4% After At-Home Alzheimer’s Therapy and Dravet Data Updates
Sep 6, 2025 • Yahoo Finance
H.C. Wainwright reiterates Buy rating on Biogen stock, citing strong lupus franchise
Sep 5, 2025 • Investing.com
Optum: 3 emerging specialty drugs payers should be watching
Sep 5, 2025 • Fierce Healthcare
Biogen (BIIB) Stock Trades Down, Here Is Why
Sep 4, 2025 • Yahoo Finance
Biogen Participating in the Cantor Global Healthcare Conference
Sep 4, 2025 • Biogen
Biogen (BIIB) Stock Trades Down, Here Is Why
Sep 4, 2025 • Stock Story
Central Nervous System Therapeutic Market is Set to Hit US$ 235.87 Billion by 2033 | Astute Analytica
Sep 4, 2025 • AstuteAnalytica India Pvt. Ltd.
Biogen Highlights Multiple Assets and Indications in Lupus
Sep 3, 2025 • Biogen
The Oligonucleotide Therapeutics Society Announces the 21st Annual Meeting in Budapest, Hungary
Sep 3, 2025 • South Africa Today
Eisai moves swiftly to expand subcutaneous Leqembi label
Sep 3, 2025 • pharmaphorum
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer’s disease under Fast Track status
Sep 3, 2025 • News Powered by Cision
Biogen, Eisai Begin FDA Rolling Submission for Early Alzheimer's Disease Drug
Sep 3, 2025 • MarketScreener
Global drugmakers rush to boost US presence as tariff threat looms
Sep 3, 2025 • MarketScreener
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
Sep 3, 2025 • BioSpace
Biogen (BIIB) Stock Is Up, What You Need To Know
Sep 2, 2025 • Yahoo Finance
Biogen to Participate in Upcoming Healthcare Conferences
Sep 2, 2025 • Biogen
North American Morning Briefing : Stock Futures Fall; Gold Hovers Near Record High
Sep 2, 2025 • MarketScreener
Stoke Therapeutics and Biogen Present Data at the 36th In...
Sep 2, 2025 • PharmiWeb
Biogen, Eisai Win FDA Nod for Subcutaneous Maintenance Leqembi
Sep 2, 2025 • BioSpace
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
Sep 2, 2025 • BioSpace
'Brainwave' test raises hopes of early dementia diagnosis
Sep 2, 2025 • pharmaphorum
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
Sep 2, 2025 • Morningstar.com
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
Sep 2, 2025 • Newswire
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
Sep 2, 2025 • Business Wire
Stoke, Biogen announce data from open-label extension studies of zorevunersen
Sep 2, 2025 • thefly.com
Stocks making the biggest premarket moves: Kraft Heinz, PepsiCo, Biogen, Signet Jewelers and more
Sep 2, 2025 • Market Insider
Alzheimer’s Therapy Is Coming to the Home With FDA Approval of Injectable Eisai, Biogen Drug
Sep 2, 2025 • MedCity News
Biogen, Stoke presents data from Phase 1/2a, OLE studies of zorevunersen
Sep 2, 2025 • thefly.com